secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001558370-24-004570
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma 2023 net loss $30.2M; expects top-line data this month for NRX-101 TRBD trial
--------------------------------------------------------------------------------

- Net loss for full-year 2023: $30.2M vs $39.8M in 2022; Q4 2023 loss $4.3M vs $10.2M in Q4 2022.
- Cash $4.6M at Dec 31, 2023; added $8M in Q1 2024 via equity sales and $5.1M milestone from Alvogen/Lotus.
- Expects top-line data in April 2024 from Phase 2b/3 trial of NRX-101 in TRBD; achieved 94% rater concordance.
- Plans to spin out HOPE Therapeutics for IV Ketamine; NDA filing expected by June 2024; term sheets for $60M investment.
- Reduced G&A expenses 50% YoY to $14.2M in 2023 from $27.3M; corporate overhead decreased by half.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/0001558370-24-004570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/nrxp-20240401x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer